About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:3815534
Allelic
Composition
Tg(KRT5-tTA)1216Glk/0
Tg(tetO-TGFB1*C223S*C225S)1Glk/0
Genetic
Background
involves: FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
N
• when pregnant mice are maintained on 10 ug/ml or higher doxycycline, double-transgenic mice with normal morphology are born at expected ratios
• 1-5 ug/ml doxycycline treatment during gestation allows full-term development of double-transgenic mice, but pups are born dead or die shortly after birth
• no live animals are obtained in litters born when the pregnant mouse does not receive doxycycline during gestation

growth/size/body
• animals born dead or dying shortly after birth with 1-5 ug/ml doxycycline treatment during gestation are runted

immune system
• weanlings treated by doxycycline withdrawal displays a variable neutrophilic infiltrate characterized by microabcesses within and above cornified layers
• weanlings treated by doxycycline withdrawal develop dermatitis on scalp and shoulders, as well as ventral surface; dermatitis extends caudally with time

cellular
• cell proliferation in the epidermis is significantly reduced in double transgenic newborns after 1-5 ug/ml doxycycline treatment during gestation

integument
• abnormalities manifest several weeks later than in Tg(tetO-TGFB1*C223S*C225S)1Glk/Tg(KRT5-rtTA)1Glk double-transgenic mice treated with doxycycline
• with reintroduction of doxycycline at >5 ug/ml in diet, nearly complete hair regrowth is observed within 14 days
• weanlings treated by doxycycline withdrawal display progressive hair loss
• in weanlings treated by doxycycline withdrawal, many hair follicles appear hyperplastic with abnormal morphologies
• hair follicle density is reduced in affected newborns after 1-5 ug/ml doxycycline treatment during gestation
• hyperkeratosis and other abnormalities manifest several weeks later than in Tg(tetO-TGFB1*C223S*C225S)1Glk/Tg(KRT5-rtTA)1Glk double-transgenic mice treated with doxycycline
• with reintroduction of doxycycline at >5 ug/ml in diet, hyperkeratotic phenotype is reversed
• dermal layer in affected double-transgenic newborns is hypervascular after 1-5 ug/ml doxycycline treatment during gestation
• significant thickening is observed in weanlings treated by doxycycline withdrawal
• affected double-transgenic newborns after 1-5 ug/ml doxycycline treatment during gestation have reduced number of cornified layers
• weanlings treated by doxycycline withdrawal develop hyperkeratosis
• epidermis of affected mice (weanlings treated by doxycycline withdrawal) becomes acanthotic
• epidermis of affected mice (weanlings treated by doxycycline withdrawal) exhibits hyperplasia
• epidermis is thinner in affected double-transgenic newborns than single-transgenic pups
• animals born dead or dying shortly after birth with 1-5 ug/ml doxycycline treatment during gestation have shiny tight erythemic skin
• abnormalities manifest several weeks later than in Tg(tetO-TGFB1*C223S*C225S)1Glk/Tg(KRT5-rtTA)1Glk double-transgenic mice treated with doxycycline
• weanlings treated by doxycycline withdrawal displays a variable neutrophilic infiltrate characterized by microabcesses within and above cornified layers
• weanlings treated by doxycycline withdrawal develop dermatitis on scalp and shoulders, as well as ventral surface; dermatitis extends caudally with time


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
01/06/2026
MGI 6.24
The Jackson Laboratory